Figure 5
From: Targeting Mcl-1 by a small molecule NSC260594 for triple-negative breast cancer therapy
NSC260594 treatment increases the apoptosis in TNBCs. (A). Cell apoptosis was detected using an Alexa Fluor® 488 Annexin V/Dead Cell Apoptosis Kit. The cells were processed according to the manufacturer's instructions using a FACS Calibur instrument. The Annexin V and PI positive cells of (B) MDA-MB-231 (C) MDA-MB468 and (D) MDA-MB-468 were counted using FlowJo software. NSC260594 treatment increased the apoptosis markers in MDA-MB-231, (E) MDA-MB-468, and (F) 4175 cells. Cells were grown in DMEM with 10% FBS overnight. The cells were then treated with DMSO, 10 μM, and 20 μM NSC260594 for 48 h. The proteins including Mcl-1, cleaved caspase 3, and cleaved PARP were detected by western blot assay. Cell cytoskeleton protein Vinculin was used as a protein loading control. Data shown represent the mean ± SD from three independent experiments, each performed in triplicate. Statistically significant values of ***p < 0.001 were determined compared with the control.
